Welcome, Guest
Username: Password: Remember me

TOPIC: (IPCI) Mcap $39 M // 8 Drugs awaiting FDA approval // 2 Approvals coming within 4 months

(IPCI) Mcap $39 M // 8 Drugs awaiting FDA approval // 2 Approvals coming within 4 months 6 years 2 weeks ago #3724

FIRST FDA APPROVAL EXPECTED IN THIS 3Q 2013....

This LOW FLOAT Monster awaiting 8 FDA approvals.IPCI has 15 Drugs in Pipeline many nearing ANDA/NDA filing including two Potential Blockbuster .CEO is the largest Shareholder with over 6 Million Shares .

FOCALIN alone which is Partnered with Par Pharma will drive this Sleeping Giant into Profitability quickly after Market Launch because of the low Burn-rate of around $7 M a year !

4-6 FDA APPROVALS COMING WITHIN NEXT 12 MONTHS = NEXT BILLION DOLLAR COMPANY HERE !

Patience here will payoff big time ! GLTA

Intellipharmaceutics (IPCI)

Market Cap:$ 38 M
Price: $1.90

Shares Out: 21 Mil..(10 Mil Shares held by Insiders/Institutions)
Low Float: 11 M


Fact Sheet
http://files.shareholder.com/downloads/ABEA-43EQSZ/2585698802x0x658021/ff542b5d-08fa-4660-8ff2-b9f36580b389/IPCI_April_Fact_Sheet.pdf


8 Generic Drug Applications Filed with the FDA
We currently have eight Abbreviated New Drug Applications awaiting FDA approval. These include generics of Focalin XR® Effexor XR®, Protonix ®' Glucophage ® XR,Seroquel XR®, Lamictaf® XR Keppra XR® and Pristiq® .Together, these products represent approximately $4.78 of branded and generic sales.

Our lead product, a generic version of Focal in XR®, is partnered with Par Pharmaceuticals Inc., a top ten U.S.pharmaceutical company.As a result of a settlement with the innovator company, we expect to marketing of our generic versions ofFocalin XR® upon approval. We have a ten year profit-sharing agreement with Par for the sale of a generic version of Focal in XR® in the U.S.,which commences with the commercia/launch of the product by Par .
The administrator has disabled public write access.